血清Ⅰ型胶原氨基端延长肽和β-Ⅰ型胶原羧基端肽与2型糖尿病合并骨质疏松性骨折相关性分析

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (560 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the correlation between serum type Ⅰ collagen amino terminal prolongation peptide (P1NP) and β-type Ⅰ collagen carboxy terminal peptide (β-CTX) and type 2 diabetes mellitus (T2DM) with osteoporosis fracture. Methods A total of 120 T2DM patients with osteoporosis fracture at the First Affiliated Hospital of Air Force Medical University of the People′s Liberation Army from June 2016 to January 2019 were selected and divided into T2DM osteoporosis with fracture group (54 cases) and T2DM osteoporosis without fracture group (66 cases). Plasma P1NP, β-CTX were measured by chemiluminescence method, and bone density, fasting blood glucose (FBG), body mass index (BMI), glycated hemoglobin (GHb), serum 25 hydroxyvitamin D [25 (OH)D] were measured, and the Pearson product correlation coefficient r was used to express the linear relationship. Results The levels of P1NP and β-CTX in T2DM osteoporosis with fracture group were lower than those in T2DM osteoporosis without fracture group (all P ＜ 0.05). P1NP and β-CTX were not significantly correlated with age, FBG, GHb, body mass index, BMI and 25 (OH)D in the two groups (P ＞ 0.05), but P1NP was positively correlated with β-CTX in the two groups (r = 0.744, 0.495, all P ＜ 0.05). Conclusion The levels of P1NP and β-CTX may be related to osteoporotic fracture in T2DM.

Key words： Type 2 diabetes mellitus Osteoporotic fracture Bone mineral density Type Ⅰ collagen amino terminal prolongation peptide β-type Ⅰ collagen carboxy terminal peptide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Xu CAO Li ZHAO Xiong WANG Qian

Cite this article:

XU Xu CAO Li ZHAO Xiong WANG Qian. Correlation analysis between serum type Ⅰ collagen amino terminal prolongation peptide and β-type Ⅰ collagen carboxy terminal peptide and type 2 diabetes mellitus with osteoporotic fracture[J]. 中国医药导报, 2020, 17(30): 88-90,98.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I30/88

[1] 张智海，刘忠厚，石少辉，等.中国大陆地区以-2.5SD为诊断的骨质疏松症发病率文献回顾性研究[J].中国骨质疏松杂志，2015，22（1）：1-7.
[2] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：34-86.
[3] 贾海梅，蔡艳丽.骨代谢指标NBAP、BGP、CTX与2型糖尿病合并骨质疏松的相关性研究[J].标记免疫分析与临床，2019，26（2）：225-229.
[4] Alberti KG，Zimmet PZ. Definition，diagnosis and classification of diabetes mellitusand its complications. Report of a WHO Consultation [J]. Diabetic Med，1999，15（7）：539-553.
[5] Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis：synopsis of a WHO report. WHO Study Group [J]. Osteoporos Int，1994， 4（6）：368-381.
[6] 章亚娣，寿柳梅，周小娟，等.中老年2型糖尿病患者骨质疏松骨折风险分析[J].全科医学临床与教育，2017，15（3）：305-306.
[7] Komorita Y，Iwase M，Fujii H，et al. Serum adiponectin predicts fracture risk in individuals with type 2 diabetes： the Fukuoka Diabetes Registry [J]. Diabetologia，2017，60（10）：1922-1930.
[8] 贾觉睿智.2型糖尿病对骨质疏松性骨折的影响及机制探索—5年前瞻性研究[D].北京：北京协和医学院，2015.
[9] 孟彩云，庄扬名.2型糖尿病并发骨质疏松患者胰岛素样生长因子-1、骨碱性磷酸酶及1,25羟维生素D3表达水平及意义[J].临床军医杂志，2019，47（6）：628-629.
[10] Anagnostis P，Paschou SA，Gkekas NN，et al. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus：a systematic review [J]. Endocrine，2018，60（3）：373-383.
[11] Yamamoto M，Yamaguchi T，Nawata K，et al. Decreased PTH Levels Accompanied by Low Bone Formation Are Associated with Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes [J]. J Clin Endoc Metab，2012，97（4）：1277-1284.
[12] 申力，邢丽莉，李鸿江，等.骨代谢标志物变化情况与绝经后女性发生骨质疏松性椎体压缩骨折的相关性分析[J].颈腰痛杂志，2019，40（3）：305-307.
[13] 唐淑尧，牛强龙，沈自雄，等.甘肃地区2型糖尿病患者骨密度变化及影响因素[J].中国骨质疏松杂志，2019， 25（7）：988-993.
[14] 袁小青，刘娟，周亮，等.不同年龄段女性2型糖尿病患者骨代谢标志物与骨密度的变化[J].实用临床医药杂志，2018，22（19）：1-6.
[15] Jiang N，Xia W. Assessment of bone quality in patients with diabetes mellitus [J]. Osteoporosis Int，2018，29（8）：1721-1736.
[16] 王萍，姜国良.老年2型糖尿病患者血清胰岛素与骨密度及骨代谢指标的相关性分析[J].山东医药，2017，57（14）：71-73.
[17] 王健民，高启红，邱守芳，等.骨硬化蛋白和dkk1与2型糖尿病患者骨密度相关性研究[J].中国骨质疏松杂志，2019，25（7）：924-928.
[18] 应蓉，龚仪雯，顾涛，等.老年女性2型糖尿病患者合并骨质疏松的临床因素分析[J].中国医刊，2017，52（12）：51-54.
[19] 谢冰秀，王灶明，张康婧.新诊断2型糖尿病患者骨密度与骨代谢指标相关性研究[J].中国医药科学，2020， 10（7）：269-271，275.
[20] 杨世伟，马荣军，赵娟娟，等.血清β-CTX/PINP在多发性骨髓瘤骨病及骨转移瘤中的临床意义[J].中华医学杂志，2018，98（32）：2583-2587.
[21] Oshagbemi OA，Driessen JHM，Pieffers A，et al. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis [J]. Osteoporosis Int，2017，28（10）：2859-2866.
[22] Yokomoto-Umakoshi M，Kanazawa I，Kondo S，et al. Association between the risk of falls and osteoporotic fractures in patients with type 2 diabetes mellitus [J]. Endocr J，2017，64（7）：727-734.
[23] 云丽媛，吴文侠，李建林.超声骨密度仪诊断2型糖尿病并发桡骨远端骨折患者骨质疏松的应用研究[J].河北医药，2019，41（17）：2671-2673，2677.